Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs-February 2024-www.financetom.com

Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs

Nov 13, 2025 11:40 AM

(Reuters) -Novo Nordisk and Eli Lilly ( LLY ) do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc ( MGRX ), spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers.

Spokespeople for both companies said in emails to Reuters that they had no special arrangements with the company.

Mangoceuticals ( MGRX ) did not respond to request for comment.

Previous page： Irth Capital raising assets for constructivist fund, Abbot to lead effort Next page： Sweetgreen Names New CFO

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Irth Capital raising assets for constructivist fund, Abbot to lead effort

Sep 4, 2025

NEW YORK (Reuters) -Irth Capital Management, the global alternative asset management firm that invests in both public and private equity, plans to raise a new investment vehicle with the goal of gently but firmly influencing companies, two sources told Reuters. The new vehicle aims to become a constructivist hedge fund where the team will pursue a strategy of suggesting changes...

Sweetgreen Names New CFO

Sep 4, 2025

05:46 PM EDT, 09/04/2025 (MT Newswires) -- Sweetgreen ( SG ) said late Thursday it has named Jamie McConnell as its chief financial officer, starting Sept. 22. McConnell will succeed Mitch Reback, who is retiring on Sept. 21, the firm said. Reback will retain an advisory role for six months to ensure a smooth transition. McConnell most recently served as...

Irth Capital raising assets for constructivist fund, Abbot to lead effort

Sep 4, 2025

NEW YORK, Sept 4 (Reuters) - Irth Capital Management, the global alternative asset management firm that invests in both public and private equity, plans to raise a new investment vehicle with the goal of gently but firmly influencing companies, two sources told Reuters. The new vehicle aims to become a constructivist hedge fund where the team will pursue a strategy...

Halozyme Therapeutics Insider Sold Shares Worth $4,444,626, According to a Recent SEC Filing

Sep 4, 2025

05:46 PM EDT, 09/04/2025 (MT Newswires) -- Helen Torley, Director, President and CEO, on September 02, 2025, sold 60,000 shares in Halozyme Therapeutics ( HALO ) for $4,444,626. Following the Form 4 filing with the SEC, Torley has control over a total of 733,719 common shares of the company, with 733,719 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1159036/000141588925023720/xslF345X05/form4-09042025_090922.xml ...